Phase I study of pegylated liposomal doxorubicin and the multidrug-resistance modulator, valspodar

Valspodar, a P-glycoprotein modulator, affects pharmacokinetics of doxorubicin when administered in combination, resulting in doxorubicin dose reduction. In animal models, valspodar has minimal interaction with pegylated liposomal doxorubicin (PEG-LD). To determine any pharmacokinetic interaction in...

Descripción completa

Detalles Bibliográficos
Autores principales: Fracasso, P M, Blum, K A, Ma, M K, Tan, B R, Wright, L P, Goodner, S A, Fears, C L, Hou, W, Arquette, M A, Picus, J, Denes, A, Mortimer, J E, Ratner, L, Ivy, S P, McLeod, H L
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2005
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361488/
https://www.ncbi.nlm.nih.gov/pubmed/15942626
http://dx.doi.org/10.1038/sj.bjc.6602653

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361488/
https://www.ncbi.nlm.nih.gov/pubmed/15942626
http://dx.doi.org/10.1038/sj.bjc.6602653

Ejemplares similares